Patents Examined by Jeffrey Mark Sifford
-
Patent number: 11998580Abstract: The present disclosure provides a liquid formulation suitable for a group B adenovirus, comprising: a) a group B adenovirus, such as replication competent group B adenovirus, b) 15 to 25% v/v glycerol, for example 16, 17, 18, 19, 20, 21% v/v glycerol; and c) 0.1 to 1.5% v/v ethanol, for example 0.2-1%, such as 1% v/v ethanol; and d) a buffer, and e) optionally an amino acid, wherein the pH of the formulation is in the range 8.0 to 9.6, and use of the same in treatment, particular in the treatment of cancer.Type: GrantFiled: January 31, 2019Date of Patent: June 4, 2024Assignee: AKAMIS BIO LIMITEDInventors: Simon Alvis, Magdalena Kieltyka
-
Patent number: 11993790Abstract: The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease (PD) and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding beta-Glucocerebrosidase (GBA) or a portion thereof alone or in combination with one or more PD-associated genes. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.Type: GrantFiled: October 3, 2018Date of Patent: May 28, 2024Assignee: Prevail Therapeutics, Inc.Inventors: Asa Abeliovich, Laura Heckman, Herve Rhinn
-
Patent number: 11986502Abstract: Compositions for affecting the intestinal microbiome of a mammalian subject can include a pharmaceutically-acceptable carrier and greater than or equal to 1×104 PFU/mL or PFU/mg of bacteriophage having a tropism that includes an obesogenic and/or inflammatory bacterium associated with an intestinal microbiome of a mammal. Processes for preparing the disclosed compositions can include isolating the bacteriophage from an environmental source, characterizing the bacteriophage, and combining the bacteriophage with the pharmaceutically acceptable carrier at greater than or equal to 1×104 PFU/mL or PFU/mg. Methods can include administering the disclosed compositions to a mammalian subject with or without co-administration of the disclosed probiotics.Type: GrantFiled: May 23, 2019Date of Patent: May 21, 2024Assignee: Optium, LLCInventors: Laura Bridgewater, Gongze Zhao
-
Patent number: 11957745Abstract: The present disclosure is directed to antibodies binding to and neutralizing Japanese Encephalitis virus and methods for use thereof.Type: GrantFiled: February 22, 2019Date of Patent: April 16, 2024Assignee: VANDERBILT UNIVERSITYInventor: James E. Crowe, Jr.
-
Patent number: 11952400Abstract: Provided are a bovine rotavirus fusion protein and calf diarrhea multivalent vaccine. The bovine rotavirus fusion protein contains a VP6 fragment, wherein the VP6 fragment contains an amino acid sequence as represented by SEQ ID NO. 4, and at least one loop region of the following (a)˜(c) is substituted with an antigenic epitope derived from bovine coronavirus and/or an antigenic epitope derived from E. coli: (a) amino acid residues of sites 168-177; with an amino acid sequence as represented by SEQ ID NO. 1; (b) amino acid residues of sites 194-205; with an amino acid sequence as represented by SEQ ID NO. 2; and (a) amino acid residues of sites 296-316, with an amino acid sequence as represented by SEQ ID NO. 3, The bovine rotavirus fusion protein contains a plurality of antigenic epitopes, and can enable a host to generate a plurality of antibodies after immunizing the host.Type: GrantFiled: April 16, 2021Date of Patent: April 9, 2024Assignee: TECON BIOPHARMACEUTICAL CO., LTD.Inventors: Sun He, Yiping Pan, Guoqing Zhang, Pengxian Yan, Na Xi, Miaomiao Guo, Shengdong Xiao, Tianzeng Li, Rui Han, Yumeng Wang, Jiubin Du, Pei Zheng, Jian Cao
-
Patent number: 11918637Abstract: The invention relates to compositions and methods for treating or preventing diseases caused by Porcine circoviruses. The invention particularly discloses methods for controlling PCV infection or disease in a pig herd, comprising (i) vaccinating sows against PCV at weaning, and (ii) vaccinating piglets against PCV at an age of between 2 to 7 weeks.Type: GrantFiled: June 10, 2019Date of Patent: March 5, 2024Inventor: Roman Krejci
-
Patent number: 11857621Abstract: A pDNA-based vaccine against SARS-CoV-2 and methods for preventing or treating COVID-19 using it. The pDNA-vaccine encodes an immunogenic portion of SARS-CoV S1 protein, such as that encoded by SEQ ID NO: 1 or a fragment thereof, and may be conveniently administered intramuscularly without the need for electroporation or use of a gene gun.Type: GrantFiled: May 18, 2021Date of Patent: January 2, 2024Assignee: Imam Abdulrahman Bin Faisal UniversityInventor: Iman Almansour
-
Patent number: 11801296Abstract: Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate (“ASFV-G”). An exemplary vaccine comprises the ASFV-G?A137R modified virus, a recombinant ASFV-G modified by deleting a portion of the A137R ORF rendering the A137R gene nonfunctional.Type: GrantFiled: June 30, 2021Date of Patent: October 31, 2023Assignee: The United States of America, as represented by The Secretary of AgricultureInventors: Douglas P. Gladue, Manuel V. Borca
-
Patent number: 11780888Abstract: The disclosure relates to a polypeptide comprising, or consisting of, the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 9 or a sequence having at least 97%-100% sequence identity to one of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 9 for use as an immunogen for the purpose of eliciting an immune response in a subject susceptible to infection with a coronavirus. The disclosed polypeptide is further useful in reducing the severity of symptoms associated with a coronavirus infection. In addition to use in a protein-based vaccine, the polypeptide of the disclosure can be encoded by a nucleic acid/ribonucleic acid and used in a nucleic acid vaccine or viral vector vaccine.Type: GrantFiled: July 22, 2021Date of Patent: October 10, 2023Inventors: Arlene I. Ramsingh, Janice Pata